New therapy for pancreatic cancer based on extracellular vesicles

Araujo-Abad, Salomé; Manresa-Manresa, Antonio; Rodrı́guez-Cañas, E.; Fuentes-Baile, María; García-Morales, Pilar; Mallavia, Ricardo; Saceda, Miguel; Romero, Camino de Juan

doi:10.1016/j.biopha.2023.114657

Cited by 4 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S. Araujo-Abad et al utilized small EVs derived from the RWP-1 cell line and loaded them with two chemotherapeutic drugs, temozolomide or EPZ015666, aiming to enhance the effectiveness of chemotherapy for treating PDAC, the most common aggressive form of PC. They observed a greater antiproliferative effect of temozolomide-loaded EVs compared to EPZ015666-loaded EVs when used in a PC cell line [ 149 ]. In a comparative investigation of various methods for loading EVs with chemotherapeutic agents, namely electroporation, sonication, and incubation with paclitaxel (PTX) and gemcitabine (GEM), it was demonstrated that sonication achieved superior efficiency in drug loading compared to incubation and electroporation.…”

Section: Structural Gastroenteric Disease and Ev-based Therapymentioning

confidence: 99%

“…PDAC cell death via clathrin-mediated endocytosis [149,150] Engineered small EVs with high CD47 expression and c(RGDyC) modification to deliver short RNAi against YTHDF1: a novel therapeutic strategy for GC via epigenetic and immune regulation [155,166] colon IBD EVs released by MSCs and loaded with miR-146: a new strategy in the treatment of IBD in mouse models [126] EVs and bacteria-derived membrane vesicles (OMVs) derived from normal feces: restore the intestinal barrier in IBD subjects [38,127,128,167] Exo containing PSMA7 derived from saliva: an important protein biomarker for IBD [168] CRC Folic acid-modified exo-liposome hybrid nanoparticles loaded with ALKBH5 mRNA: a novel therapeutic strategy for CRC [156] EVs derived from CT26 and loaded with miR-34a mimics: a new strategy for CRC gene therapy in mouse model [159] EVs derived from milk: a reduction in primary tumor burden in mouse models of CRC and breast cancer [161,162] Exosomes secreted from HEK293T transfected with Her2-mCherry plasmid and loaded with both 5-FU and miR-21i: reversing the drug resistance in CRC cells [164,165] Exosomes secreted from MSCs modified with 5TR1 or with magnetic nanoparticles, folic acid, and DOXO: the inhibition of CRC growth in mouse models [151][152][153][154]…”

Section: Organ Pathology Ev-based Preparations and Applications Refer...mentioning

confidence: 99%

See 1 more Smart Citation

Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases

Arrè,

Mastrogiacomo,

Balestra

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Extracellular vesicles (EVs), acting as inherent nanocarriers adept at transporting a range of different biological molecules such as proteins, lipids, and genetic material, exhibit diverse functions within the gastroenteric tract. In states of normal health, they participate in the upkeep of systemic and organ homeostasis. Conversely, in pathological conditions, they significantly contribute to the pathogenesis of gastrointestinal diseases (GIDs). Isolating EVs from patients’ biofluids facilitates the discovery of new biomarkers that have the potential to offer a rapid, cost-effective, and non-invasive method for diagnosing and prognosing specific GIDs. Furthermore, EVs demonstrate considerable therapeutic potential as naturally targeted physiological carriers for the intercellular delivery of therapeutic cargo molecules or as nanoscale tools engineered specifically to regulate physio-pathological conditions or disease progression. Their attributes including safety, high permeability, stability, biocompatibility, low immunogenicity, and homing/tropism capabilities contribute to their promising clinical therapeutic applications. This review will delve into various examples of EVs serving as biomarkers or nanocarriers for therapeutic cargo in the context of GIDs, highlighting their clinical potential for both functional and structural gastrointestinal conditions. The versatile and advantageous properties of EVs position them as promising candidates for innovative therapeutic strategies in advancing personalized medicine approaches tailored to the gastroenteric tract, addressing both functional and structural GIDs.

show abstract

Section: Structural Gastroenteric Disease and Ev-based Therapymentioning

confidence: 99%

Section: Organ Pathology Ev-based Preparations and Applications Refer...mentioning

confidence: 99%

Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases

Arrè,

Mastrogiacomo,

Balestra

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer

Araujo-Abad,

Berna,

Lloret-Lopez

et al. 2024

Cell Oncol.

View full text Add to dashboard Cite

Extracellular vesicles as drug delivery systems in therapeutics: current strategies and future challenges

Lu,

Fan,

Cao

et al. 2024

J. Pharm. Investig.

View full text Add to dashboard Cite

Background Extracellular vesicles (EVs), which are nanometer-sized vesicles enclosed by lipid membranes, are secreted by most cells and contain lipids, proteins, and various nucleic acid species from the source cell. Due to their natural origin, high biocompatibility, stability, targeting ability, multifunctionality, and low immunogenicity, EVs have been increasingly explored as potential drug delivery system (DDS) agents, offering new strategies for the treatment of cardiovascular disease, neurodegenerative disease, cancer and many other diseases. However, there are several challenges facing EVs as drug delivery systems, such as the low drug loading efficiency and the need for consensus on ideal cell types as sources for EVs at the clinical level. Area Covered This article briefly reviews the physiological characteristics of EVs and discusses the applicable conditions for endogenous and exogenous drug loading in EVs, as well as the delivery modes of EVs as carriers. Finally, the challenges of EVs stability and drug encapsulation efficiency of EVs as future DDS are also described. Expert Opinion This article mainly focused on the different methods of endogenous and exogenous drug loading, described the delivery modes of EVs as carriers in drug delivery, and the challenges of stability and drug encapsulation efficiency facing in the future in detail and deeply.

show abstract

New therapy for pancreatic cancer based on extracellular vesicles

Cited by 4 publications

References 58 publications

Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases

Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases

Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer

Extracellular vesicles as drug delivery systems in therapeutics: current strategies and future challenges

Contact Info

Product

Resources

About